Creative Medical Health to Recruit Principal Investigator for U.S. Clinical Trial on Use of Stem Cells for Treatment of Erectile Dysfunction
Creative Medical Health, Inc. (CMH) announced today initiation of efforts to recruit a preeminent U.S. urologist as principal investigator to run a Phase I/II study under FDA jurisdiction assessing efficacy of its patented method of treating erectile dysfunction.
Creative Medical Health Inc (CMH) announced today the commercial launch of Natural Rest™, a bionutraceutical product containing natural ingredients that have been scientifically proven to enhance sleep and reduce anxiety in independent studies.
Creative Medical Health announced today the issuance of a trademark from the European Union to protect the company’s “Bionutraceutical®” designation. The term, which is trademarked in the United States and E.U. and pending in other countries, was coined by Creative Medical Health to define a new tier of health products, distinct from nutraceuticals and pharmaceuticals.
Creative Medical Health announced today filing of intellectual property covering the utilization of its proprietary mesenchymal stem cell-based product for treatment for autoimmune diseases, with multiple sclerosis being the first disease in which the product will be clinically assessed. The patent covers various modifications and cell types that are used to specifically stop the immunological processes that cause inflammation in the nervous system, which leads to the pathology seen in multiple sclerosis. Multiple sclerosis affects approximately 23 million patients, with a global market for disease-modifying products that reached nearly $10.9 billion in 2013. This is estimated to grow to nearly $14.2 billion by 20181.